子宫内膜癌组织中Ki-67、Bcl-2、p53蛋白表达变化及意义
|
摘要
目的观察子宫内膜癌组织中Ki-67、Bcl-2、p53蛋白表达变化,并探讨其临床意义。方法收集术中切除的子宫内膜癌组织60例作为观察组,20例子宫肌瘤、20例单纯性增生、10例复杂性增生患者的子宫正常内膜组织作为对照组。采用免疫组化染色技术检测两组Ki-67、Bcl-2和p53蛋白表达并作比较,分析Ki-67、Bcl-2及p53蛋白表达与子宫内膜癌患者临床病理参数的关系。结果观察组Ki-67、Bcl-2及p53蛋白阳性表达率高于对照组(P均<0.05)。子宫内膜癌组织中Ki-67蛋白阳性表达与患者年龄无关(P>0.05),与肿瘤临床分期、肌层浸润程度、淋巴结转移、分化程度有关(P均<0.05);Bcl-2蛋白阳性表达与年龄、肌层浸润程度、淋巴结转移无关(P均>0.05),与肿瘤临床分期、分化程度有关(P均<0.05);p53蛋白阳性表达与年龄、肌层浸润程度无关(P均>0.05),与肿瘤临床分期、淋巴结转移、分化程度有关(P均<0.05)。结论子宫内膜癌组织中Ki-67、Bcl-2及p53蛋白均呈高表达,且均与肿瘤临床分期、分化程度有关。
Objective To investigate the expression changes of Ki-67,Bcl-2 and p53 in the endometrial cancer tissues and their clinical significance. Methods Sixty cases of endometrial carcinoma tissues removed from the surgery were collected as the observation group. The endometrial tissues from 20 patients with uterine fibroids,20 patients with simple hyperplasia,and 10 patients with complicated hyperplasia were collected as the control group. The expression of Ki-67,Bcl-2,and p53 was measured and compared by immunohistochemistry staining between two groups. The relationship between the expression of Ki-67,Bcl-2 and p53 and clinicopathological features of patients with endometrial carcinoma was analyzed. Results The positive expression rates of ki-67,Bcl-2 and p53 in the observation group were significantly higher than those in the control group( P < 0. 05). The expression of Ki-67 in the endometrial carcinoma tissues was positively correlated with clinical stage,myometrial invasion,lymph node metastasis,and degree of differentiation( P < 0. 05),whereas was not correlated with age( P > 0. 05); the expression of Bcl-2 was positively correlated with clinical stage,and differentiation degree( both P < 0. 05),whereas was not correlated with age,muscle layer infiltration,or lymph node metastasis( all P > 0. 05); the expression of p53 in the endometrial carcinoma tissues was positively correlated with clinical stage,lymph node metastasis,and degree of differentiation( P < 0. 05),but was not correlated with age or myometrial invasion( both P > 0. 05). Conclusion Ki-67,Bcl-2,and p53 protein are highly expressed in the endometrial carcinoma tissues,which are all related to clinical stage and differentiation degree.
Objective To investigate the expression changes of Ki-67,Bcl-2 and p53 in the endometrial cancer tissues and their clinical significance. Methods Sixty cases of endometrial carcinoma tissues removed from the surgery were collected as the observation group. The endometrial tissues from 20 patients with uterine fibroids,20 patients with simple hyperplasia,and 10 patients with complicated hyperplasia were collected as the control group. The expression of Ki-67,Bcl-2,and p53 was measured and compared by immunohistochemistry staining between two groups. The relationship between the expression of Ki-67,Bcl-2 and p53 and clinicopathological features of patients with endometrial carcinoma was analyzed. Results The positive expression rates of ki-67,Bcl-2 and p53 in the observation group were significantly higher than those in the control group( P < 0. 05). The expression of Ki-67 in the endometrial carcinoma tissues was positively correlated with clinical stage,myometrial invasion,lymph node metastasis,and degree of differentiation( P < 0. 05),whereas was not correlated with age( P > 0. 05); the expression of Bcl-2 was positively correlated with clinical stage,and differentiation degree( both P < 0. 05),whereas was not correlated with age,muscle layer infiltration,or lymph node metastasis( all P > 0. 05); the expression of p53 in the endometrial carcinoma tissues was positively correlated with clinical stage,lymph node metastasis,and degree of differentiation( P < 0. 05),but was not correlated with age or myometrial invasion( both P > 0. 05). Conclusion Ki-67,Bcl-2,and p53 protein are highly expressed in the endometrial carcinoma tissues,which are all related to clinical stage and differentiation degree.
引文
[1]Le C,He W,Yang Q.CRKL overexpression promotes cell proliferation and inhibits apoptosis in endometrial carcinoma[J].Oncol Lett,2017,13(1):51-56.
[2]丁堪铄,卢丽娜,余莉萍,等.C-erb B-2、p53、Ki-67、ER、PR在子宫内膜癌中的表达及临床相关性[J].实用医学杂志,2015,31(24):4069-4071.
[3]代艳芬,满霞霞,李佳佳,等.ER、PR、P53、Ki-67在子宫内膜癌组织中的表达及其临床意义[J].中国妇幼保健,2016,31(8):1606-1608.
[4]Li LH,Zhang PR,Cai PY,et al.Histone deacetylase inhibitor,Romidepsin(FK228)inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway[J].Biomed Pharmacother,2016,82:161-166.
[5]王娟,李军,郭灿灿.雌激素受体、孕激素受体、p53及Ki-67在子宫内膜癌组织中的表达及其与临床病理参数的关系[J].海南医学,2017,28(2):211-213.
[6]Deraco M,Cabras A,Baratti D,et al.Immunohistochemical evaluation of minichromosome maintenance protein 7(MCM7),topoisomeraseⅡ,and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray[J].Ann Surg Oncol,2015,22(13):4344-4351.
[7]Allen JE,Prabhu VV,Talekar M,et al.Genetic and pharmacological screens converge in identifying FLIP,BCL2,and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10[J].Cancer Res,2015,75(8):1668.
[8]Nguyen TT,Hachisuga T,Urabe R,et al.Significance of p53 expression in background endometrium in endometrial carcinoma[J].Virchows Archiv,2015,466(6):695-702.
[9]张洪涛,顾振鹏,薄其美,等.人表皮生长因子-2、突变型p53、Ki-67在早期子宫内膜腺癌组织中的表达及意义[J].中国妇幼保健,2016,31(16):3384-3387.
[10]李静亚.子宫内膜癌临床病理因素与ER、PR、p53、Ki-67相关性研究[J].齐齐哈尔医学院学报,2017,38(5):508-510.
[11]Arfaoui A,Douik H,Kablouti G,et al.Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance[J].Anticancer Res,2015,35(3):1763.
[12]夏朝晖,李文敏,何雯.子宫内膜癌PR、ER、PTEN、p53及Ki-67的表达情况及其与预后的相关性分析[J].解放军医药杂志,2017,29(7):22-25.
[13]杜宁宁,谭文举,李洪言,等.子宫内膜癌组织中miRNA-302c的表达变化及其意义[J].山东医药,2017,57(35):47-49.
[14]陈丽君,任晓丽,孙秀利,等.p53、p16、PTEN、Ki-67、p63在子宫内膜腺癌中的表达及其与预后的相关性[J].中国妇幼健康研究,2016,27(9):1157-1160.
[15]田侠,刘爱军,曹晨,等.分子标志物在子宫内膜癌中的表达分析[J].现代生物医学进展,2015,15(10):1891-1894.
[16]Liu Y,Du F Y,Chen W,et al.G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30[J].Am J Transl Res,2015,7(5):967-975.
[17]Koi C,Hachisuga T,Murakami M,et al.Overexpression of p53 in the endometrial gland in postmenopausal women[J].Menopause,2015,22(1):104-107.
[18]Hayashi H,Beppu T,Sakamoto Y,et al.Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases[J].Am J Cancer Res,2015,5(3):1225.
[19]Staff TPO.Correction:Association of genetic markers in the BCL-2family of apoptosis-related genes with endometrial cancer risk in a Chinese population[J].PLo S One,2015,10(1):e0117632.
[20]卢建军,张林燕,宋建东.P53蛋白和MGMT蛋白在子宫内膜癌中的表达及意义[J].中国妇幼保健,2015,30(8):1254-1256.
[21]Miyamoto T,Kashima H,Yamada Y,et al.Lipocalin 2 Enhances migration and resistance against cisplatin in endometrial carcinoma cells[J].PLo S One,2016,11(5):e0155220.
[2]丁堪铄,卢丽娜,余莉萍,等.C-erb B-2、p53、Ki-67、ER、PR在子宫内膜癌中的表达及临床相关性[J].实用医学杂志,2015,31(24):4069-4071.
[3]代艳芬,满霞霞,李佳佳,等.ER、PR、P53、Ki-67在子宫内膜癌组织中的表达及其临床意义[J].中国妇幼保健,2016,31(8):1606-1608.
[4]Li LH,Zhang PR,Cai PY,et al.Histone deacetylase inhibitor,Romidepsin(FK228)inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway[J].Biomed Pharmacother,2016,82:161-166.
[5]王娟,李军,郭灿灿.雌激素受体、孕激素受体、p53及Ki-67在子宫内膜癌组织中的表达及其与临床病理参数的关系[J].海南医学,2017,28(2):211-213.
[6]Deraco M,Cabras A,Baratti D,et al.Immunohistochemical evaluation of minichromosome maintenance protein 7(MCM7),topoisomeraseⅡ,and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray[J].Ann Surg Oncol,2015,22(13):4344-4351.
[7]Allen JE,Prabhu VV,Talekar M,et al.Genetic and pharmacological screens converge in identifying FLIP,BCL2,and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10[J].Cancer Res,2015,75(8):1668.
[8]Nguyen TT,Hachisuga T,Urabe R,et al.Significance of p53 expression in background endometrium in endometrial carcinoma[J].Virchows Archiv,2015,466(6):695-702.
[9]张洪涛,顾振鹏,薄其美,等.人表皮生长因子-2、突变型p53、Ki-67在早期子宫内膜腺癌组织中的表达及意义[J].中国妇幼保健,2016,31(16):3384-3387.
[10]李静亚.子宫内膜癌临床病理因素与ER、PR、p53、Ki-67相关性研究[J].齐齐哈尔医学院学报,2017,38(5):508-510.
[11]Arfaoui A,Douik H,Kablouti G,et al.Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance[J].Anticancer Res,2015,35(3):1763.
[12]夏朝晖,李文敏,何雯.子宫内膜癌PR、ER、PTEN、p53及Ki-67的表达情况及其与预后的相关性分析[J].解放军医药杂志,2017,29(7):22-25.
[13]杜宁宁,谭文举,李洪言,等.子宫内膜癌组织中miRNA-302c的表达变化及其意义[J].山东医药,2017,57(35):47-49.
[14]陈丽君,任晓丽,孙秀利,等.p53、p16、PTEN、Ki-67、p63在子宫内膜腺癌中的表达及其与预后的相关性[J].中国妇幼健康研究,2016,27(9):1157-1160.
[15]田侠,刘爱军,曹晨,等.分子标志物在子宫内膜癌中的表达分析[J].现代生物医学进展,2015,15(10):1891-1894.
[16]Liu Y,Du F Y,Chen W,et al.G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30[J].Am J Transl Res,2015,7(5):967-975.
[17]Koi C,Hachisuga T,Murakami M,et al.Overexpression of p53 in the endometrial gland in postmenopausal women[J].Menopause,2015,22(1):104-107.
[18]Hayashi H,Beppu T,Sakamoto Y,et al.Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases[J].Am J Cancer Res,2015,5(3):1225.
[19]Staff TPO.Correction:Association of genetic markers in the BCL-2family of apoptosis-related genes with endometrial cancer risk in a Chinese population[J].PLo S One,2015,10(1):e0117632.
[20]卢建军,张林燕,宋建东.P53蛋白和MGMT蛋白在子宫内膜癌中的表达及意义[J].中国妇幼保健,2015,30(8):1254-1256.
[21]Miyamoto T,Kashima H,Yamada Y,et al.Lipocalin 2 Enhances migration and resistance against cisplatin in endometrial carcinoma cells[J].PLo S One,2016,11(5):e0155220.